UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) February 26, 2007
NOVAVAX, INC.
(Exact name of Registrant as specified in its charter)
| |
|
|
|
|
| Delaware
|
|
0-26770
|
|
22-2816046 |
| (State or other jurisdiction
of incorporation or
|
|
(Commission File Number)
|
|
(I.R.S. Employer Identification No.) |
| organization) |
|
|
|
|
| |
|
|
|
|
9920 Belward Campus Drive
Rockville, Maryland
(Address of principal executive offices)
|
|
|
20850
(Zip Code) |
| |
|
|
|
|
| Registrant’s telephone number, including area code:
|
|
|
(240) 268-2000 |
508 Lapp Road, Malvern, Pennsylvania 19355
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 1.01. Entry into a Material Definitive Agreement.
On March 2, 2007, Novavax, Inc. (the “Company”) announced that it had entered into a worldwide
agreement to exclusively license a new virus-like particle (“VLP”) technology from the University
of Massachusetts Medical School. Under the agreement, the Company has the right to use this
technology to develop VLP vaccines for the prevention of any viral diseases in humans. This
technology will complement the approach that the Company has been using to create its VLP vaccines
for pandemic and seasonal influenza.
The Company intends to file a copy of the agreement with its Anuual Report on Form 10-K for the
year ended December 31, 2006. A copy of the release is furnished with this report as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
Exhibits
|
|
|
|
|
99.1 Press release issued by Novavax, Inc., dated March 2, 2007 |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused
this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
Novavax, Inc. |
| |
|
|
|
(Registrant) |
|
|
|
|
|
|
|
|
|
|
|
March 2, 2007
|
|
|
|
By:
|
/s/ Jeffrey W. Church
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Name:
|
Jeffrey W. Church |
|
|
|
|
|
|
|
|
Title:
|
Vice President, Treasurer and Chief
Financial Officer |
|
|
|
|
3